The DOI matches its Crossref record; 641 of the 641 references it cites were found in a registry or an index.
Hepatocellular carcinoma: signaling pathways and therapeutic advances
Open accessAbstract
Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% of liver cancer cases and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) and C (HCV), and metabolic disorders. There are no obvious symptoms in the early stage of HCC, which often leads to delays in diagnosis. Therefore, HCC patients usually present with tumors in advanced and incurable stages. Several signaling pathways are dis-regulated in HCC and cause uncontrolled cell propagation, metastasis, and recurrence of HCC. Beyond the frequently altered and therapeutically targeted receptor tyrosine kinase (RTK) pathways in HCC, pathways involved in cell differentiation, telomere regulation, epigenetic modification and stress response also provide therapeutic potential. Investigating the key signaling pathways and their inhibitors is pivotal for achieving therapeutic advancements in the management of HCC. At present, the primary therapeutic approaches for advanced HCC are tyrosine kinase inhibitors (TKI), immune checkpoint inhibitors (ICI), and combination regimens. New trials are investigating combination therapies involving ICIs and TKIs or anti-VEGF (endothelial growth factor) therapies, as well as combinations of two immunotherapy regimens. The outcomes of these trials are expected to revolutionize HCC management across all stages. Here, we provide here a comprehensive review of cellular signaling pathways, their therapeutic potential, evidence derived from late-stage clinical trials in HCC and discuss the concepts underlying earlier clinical trials, biomarker identification, and the development of more effective therapeutics for HCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
LI, L., & Ye, J. (2020) · Medicine · doi:10.1097/md.0000000000021788 · Cited by 57
RetractedHanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R. L., Soerjomataram, I., & Jemal, A. (2024) · CA: a cancer journal for clinicians · doi:10.3322/caac.21834 · Cited by 27,064
Sorafenib in advanced hepatocellular carcinoma
Llovet, J. M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.-F., de Oliveira, A. C., Santoro, A., Raoul, J.-L., Forner, A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708857 · Cited by 13,097
Hallmarks of Cancer: New Dimensions
Hanahan, D. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1059 · Cited by 9,887
Siegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470
Llovet, J. M., Kelley, R. K., Villanueva, A., Singal, A. G., Pikarsky, E., Roayaie, S., Lencioni, R., Koike, K., Zucman-Rossi, J., & Finn, R. S. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-00240-3 · Cited by 7,055
A New Era of Systemic Therapy for Hepatocellular Carcinoma with Regorafenib and Lenvatinib
Kudo, M. (2017) · Liver Cancer · doi:10.1159/000462153 · Cited by 5,936
Cheng, A.-L., Kang, Y.-K., Chen, Z., Tsao, C.-J., Qin, S., Kim, J. S., Luo, R., Feng, J., Ye, S., Yang, T.-S., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(08)70285-7 · Cited by 5,832
Comprehensive molecular profiling of lung adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13385 · Cited by 5,732
Kudo, M., Finn, R. S., Qin, S., Han, K.-H., Ikeda, K., Piscaglia, F., Baron, A., Park, J.-W., Han, G., Jassem, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30207-1 · Cited by 5,497
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Gut microbiota in human metabolic health and disease
Fan, Y., & Pedersen, O. (2021) · Nature Reviews Microbiology · doi:10.1038/s41579-020-0433-9 · Cited by 4,724
El-Khoueiry, A. B., Sangro, B., Yau, T., Crocenzi, T. S., Kudo, M., Hsu, C., Kim, T.-Y., Choo, S.-P., Trojan, J., Welling, T. H., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31046-2 · Cited by 4,280
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., Pracht, M., Yokosuka, O., Rosmorduc, O., Breder, V., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32453-9 · Cited by 3,653
Vignali, D. A. A., Collison, L. W., & Workman, C. J. (2008) · Nature Reviews Immunology · doi:10.1038/nri2343 · Cited by 3,463
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., Nomura, T., & Sakaguchi, S. (2008) · Science · doi:10.1126/science.1160062 · Cited by 2,956
Clonal heterogeneity and tumor evolution: past, present, and the future
McGranahan, N., & Swanton, C. (2017) · Cell · doi:10.1016/j.cell.2017.01.018 · Cited by 2,840
Critical nodes in signalling pathways: insights into insulin action
Taniguchi, C. M., Emanuelli, B., & Kahn, C. R. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1837 · Cited by 2,760
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Wnt/β-catenin signalling: function, biological mechanisms, and therapeutic opportunities
Liu, J., Xiao, Q., Xiao, J., Niu, C., Li, Y., Zhang, X., Zhou, Z., Shu, G., & Yin, G. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00762-6 · Cited by 2,519
Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma
Ally, A., Balasundaram, M., Carlsen, R., Chuah, E., Clarke, A., Dhalla, N., Holt, R. A., Jones, S. J. M., Lee, D., Ma, Y., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.046 · Cited by 2,490
Self-citationZhu, A. X., Finn, R. S., Edeline, J., Cattan, S., Ogasawara, S., Palmer, D., Verslype, C., Zagonel, V., Fartoux, L., Vogel, A., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30351-6 · Cited by 2,479
Molecular anatomy of a trafficking organelle
Takamori, S., Holt, M., Stenius, K., Lemke, E. A., Grønborg, M., Riedel, D., Urlaub, H., Schenck, S., Brügger, B., Ringler, P., et al. (2006) · Cell · doi:10.1016/j.cell.2006.10.030 · Cited by 2,373
Elucidation of a universal size-control mechanism in Drosophila and mammals
Dong, J., Feldmann, G., Huang, J., Wu, S., Zhang, N., Comerford, S. A., Gayyed, M. F., Anders, R. A., Maitra, A., & Pan, D. (2007) · Cell · doi:10.1016/j.cell.2007.07.019 · Cited by 2,370
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
Abou-Alfa, G. K., Meyer, T., Cheng, A.-L., El-Khoueiry, A. B., Rimassa, L., Ryoo, B.-Y., Cicin, I., Merle, P., Chen, Y., Park, J.-W., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1717002 · Cited by 2,344
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Forbes, S. A., Bindal, N., Bamford, S., Cole, C., Kok, C. Y., Beare, D., Jia, M., Shepherd, R., Leung, K., Menzies, A., et al. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkq929 · Cited by 2,278
The cyclin D1 gene is a target of the β-catenin/LEF-1 pathway
Shtutman, M., Zhurinsky, J., Simcha, I., Albanese, C., D’Amico, M., Pestell, R., & Ben-Ze’ev, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.10.5522 · Cited by 2,230
Global burden of primary liver cancer in 2020 and predictions to 2040
Rumgay, H., Arnold, M., Ferlay, J., Lesi, O., Cabasag, C. J., Vignat, J., Laversanne, M., McGlynn, K. A., & Soerjomataram, I. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.08.021 · Cited by 2,197
The PI3K–AKT network at the interface of oncogenic signalling and cancer metabolism
Hoxhaj, G., & Manning, B. D. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0216-7 · Cited by 2,137
The diverse functions of the PD1 inhibitory pathway
Sharpe, A. H., & Pauken, K. E. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.108 · Cited by 1,971
Immunotherapies for hepatocellular carcinoma
Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843
The primary cilium: a signalling centre during vertebrate development
Goetz, S. C., & Anderson, K. V. (2010) · Nature Reviews Genetics · doi:10.1038/nrg2774 · Cited by 1,824
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikakos, P. I., Zhang, C., Bollag, G., Shokat, K. M., & Rosen, N. (2010) · Nature · doi:10.1038/nature08902 · Cited by 1,811
Schulze, K., Imbeaud, S., Letouzé, E., Alexandrov, L. B., Calderaro, J., Rebouissou, S., Couchy, G., Meiller, C., Shinde, J., Soysouvanh, F., et al. (2015) · Nature Genetics · doi:10.1038/ng.3252 · Cited by 1,803
Williams, J. H., Phillips, T. D., Jolly, P. E., Stiles, J. K., Jolly, C. M., & Aggarwal, D. (2004) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/80.5.1106 · Cited by 1,781
The mechanisms of Hedgehog signalling and its roles in development and disease
Briscoe, J., & Thérond, P. P. (2013) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3598 · Cited by 1,751
Tumor angiogenesis: molecular pathways and therapeutic targets
Weis, S. M., & Cheresh, D. A. (2011) · Nature Medicine · doi:10.1038/nm.2537 · Cited by 1,736
Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H., & Freeman, G. J. (2007) · Immunity · doi:10.1016/j.immuni.2007.05.016 · Cited by 1,732
PI3K and cancer: lessons, challenges and opportunities
Fruman, D. A., & Rommel, C. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4204 · Cited by 1,709
Zhu, A. X., Kang, Y.-K., Yen, C.-J., Finn, R. S., Galle, P. R., Llovet, J. M., Assenat, E., Brandi, G., Pracht, M., Lim, H. Y., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30937-9 · Cited by 1,662
Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret
Schuchardt, A., D'Agati, V., Larsson-Blomberg, L., Costantini, F., & Pachnis, V. (1994) · Nature · doi:10.1038/367380a0 · Cited by 1,614
Abou-Alfa, G. K., Sahai, V., Hollebecque, A., Vaccaro, G., Melisi, D., Al-Rajabi, R., Paulson, A. S., Borad, M. J., Gallinson, D., Murphy, A. G., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30109-1 · Cited by 1,611
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Shi, Y., Au, J. S.-K., Thongprasert, S., Srinivasan, S., Tsai, C.-M., Khoa, M. T., Heeroma, K., Itoh, Y., Cornelio, G., & Yang, P.-C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000033 · Cited by 1,551
Gut microbiome–mediated bile acid metabolism regulates liver cancer via NKT cells
Ma, C., Han, M., Heinrich, B., Fu, Q., Zhang, Q., Sandhu, M., Agdashian, D., Terabe, M., Berzofsky, J. A., Fako, V., et al. (2018) · Science · doi:10.1126/science.aan5931 · Cited by 1,508
From NASH to HCC: current concepts and future challenges
Anstee, Q. M., Reeves, H. L., Kotsiliti, E., Govaere, O., & Heikenwalder, M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0145-7 · Cited by 1,392
Erdafitinib in Locally Advanced or Metastatic Urothelial Carcinoma
Loriot, Y., Necchi, A., Park, S. H., Garcia-Donas, J., Huddart, R., Burgess, E., Fleming, M., Rezazadeh, A., Mellado, B., Varlamov, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817323 · Cited by 1,360
Promotion of Hepatocellular Carcinoma by the Intestinal Microbiota and TLR4
Dapito, D. H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J. M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.02.007 · Cited by 1,346
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
Thorpe, L. M., Yuzugullu, H., & Zhao, J. J. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3860 · Cited by 1,345
Angiogenic signaling pathways and anti-angiogenic therapy for cancer
Liu, Z.-L., Chen, H.-H., Zheng, L.-L., Sun, L.-P., & Shi, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01460-1 · Cited by 1,300
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature · doi:10.1038/s41586-021-03362-0 · Cited by 1,294
Yau, T., Kang, Y.-K., Kim, T.-Y., El-Khoueiry, A. B., Santoro, A., Sangro, B., Melero, I., Kudo, M., Hou, M.-M., Matilla, A., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.4564 · Cited by 1,273
Acquired Resistance to KRAS G12C Inhibition in Cancer
Awad, M. M., Liu, S., Rybkin, I. I., Arbour, K. C., Dilly, J., Zhu, V. W., Johnson, M. L., Heist, R. S., Patil, T., Riely, G. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2105281 · Cited by 1,247
NF-κB and STAT3 – key players in liver inflammation and cancer
He, G., & Karin, M. (2011) · Cell Research · doi:10.1038/cr.2010.183 · Cited by 1,197
Garcia, J., Hurwitz, H. I., Sandler, A. B., Miles, D., Coleman, R. L., Deurloo, R., & Chinot, O. L. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102017 · Cited by 1,159
Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
Melincovici, C. S., Boşca, A. B., Șușman, S., Mărginean, M. V., Mihu, C., Istrate, M., Moldovan, I. M., Roman, A. L., & Mihu, C. M. (2018) · PubMed · Cited by 1,146
Yau, T., Park, J.-W., Finn, R. S., Cheng, A.-L., Mathurin, P., Edeline, J., Kudo, M., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00604-5 · Cited by 1,106
Stattic: a small-molecule inhibitor of STAT3 activation and dimerization
Schust, J., Sperl, B., Hollis, A., Mayer, T. U., & Berg, T. (2006) · Chemistry & Biology · doi:10.1016/j.chembiol.2006.09.018 · Cited by 1,105
Targeting TGF-β signal transduction for fibrosis and cancer therapy
Peng, D., Fu, M., Wang, M., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01569-x · Cited by 1,065
Targeting p53 pathways: mechanisms, structures, and advances in therapy
Wang, H., Guo, M., Wei, H., & Chen, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01347-1 · Cited by 1,016
Sangro, B., Gomez-Martin, C., de la Mata, M., Iñarrairaegui, M., Garralda, E., Barrera, P., Riezu-Boj, J. I., Larrea, E., Alfaro, C., Sarobe, P., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.02.022 · Cited by 980
Cancer heterogeneity: implications for targeted therapeutics
Fisher, R., Pusztai, L., & Swanton, C. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.581 · Cited by 978
Yau, T. (., Park, J. W. (.-W., Finn, R. S. (. S. )., Cheng, A. L. (.-L., Mathurin, P., Edeline, J., Kudo, M. (., Harding, J. J., Merle, P., Rosmorduc, O., et al. (2022) · Deposito Adademico Digital Universidad De Navarra (University of Navarra) · Cited by 934
Ruiz de Galarreta, M., Bresnahan, E., Molina-Sánchez, P., Lindblad, K. E., Maier, B., Sia, D., Puigvehi, M., Miguela, V., Casanova-Acebes, M., Dhainaut, M., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0074 · Cited by 912
Self-citationRas in Cancer and Developmental Diseases
Fernandez-Medarde, A., & Santos, E. (2011) · Genes & Cancer · doi:10.1177/1947601911411084 · Cited by 897
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Circulating tumour DNA methylation markers for diagnosis and prognosis of hepatocellular carcinoma
Xu, R.-H., Wei, W., Krawczyk, M., Wang, W., Luo, H., Flagg, K., Yi, S., Shi, W., Quan, Q., Li, K., et al. (2017) · Nature Materials · doi:10.1038/nmat4997 · Cited by 862
Contextual determinants of TGFβ action in development, immunity and cancer
David, C. J., & Massagué, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0007-0 · Cited by 851
Zhu, A. X., Park, J. O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., Blanc, J.-F., Chung, H. C., Baron, A. D., Pfiffer, T. E. F., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00050-9 · Cited by 846
Zhang, X., Coker, O. O., Chu, E. S., Fu, K., Lau, H. C. H., Wang, Y.-X., Chan, A. W. H., Wei, H., Yang, X., Sung, J. J. Y., et al. (2021) · Gut · doi:10.1136/gutjnl-2019-319664 · Cited by 841
Hedgehog signalling in cancer formation and maintenance
di Magliano, M. P., & Hebrok, M. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1229 · Cited by 829
p53: 800 million years of evolution and 40 years of discovery
Levine, A. J. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-020-0262-1 · Cited by 826
Zhang, N., Bai, H., David, K. K., Dong, J., Zheng, Y., Cai, J., Giovannini, M., Liu, P., Anders, R. A., & Pan, D. (2010) · Developmental Cell · doi:10.1016/j.devcel.2010.06.015 · Cited by 804
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Monounsaturated Fatty Acid Modification of Wnt Protein: Its Role in Wnt Secretion
Takada, R., Satomi, Y., Kurata, T., Ueno, N., Norioka, S., Kondoh, H., Takao, T., & Takada, S. (2006) · Developmental Cell · doi:10.1016/j.devcel.2006.10.003 · Cited by 788
Reedijk, M., Odorcic, S., Chang, L., Zhang, H., Miller, N., McCready, D. R., Lockwood, G., & Egan, S. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1069 · Cited by 783
The role of the Hedgehog signaling pathway in cancer: A comprehensive review
Skoda, A. M., Simovic, D., Karin, V., Kardum, V., Vranic, S., & Serman, L. (2018) · Bosnian Journal of Basic Medical Sciences · doi:10.17305/bjbms.2018.2756 · Cited by 781
Johnson, P. J., Qin, S., Park, J.-W., Poon, R. T. P., Raoul, J.-L., Philip, P. A., Hsu, C.-H., Hu, T.-H., Heo, J., Xu, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.48.4410 · Cited by 772
Teprotumumab for the Treatment of Active Thyroid Eye Disease
Douglas, R. S., Kahaly, G. J., Patel, A., Sile, S., Thompson, E. H. Z., Perdok, R., Fleming, J. C., Fowler, B. T., Marcocci, C., Marinò, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910434 · Cited by 752
Qin, S., Chan, S. L., Gu, S., Bai, Y., Ren, Z., Lin, X., Chen, Z., Jia, W., Jin, Y., Guo, Y., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00961-3 · Cited by 746
The gut–liver axis and gut microbiota in health and liver disease
Hsu, C. L., & Schnabl, B. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00904-3 · Cited by 737
Pivotal Role of mTOR Signaling in Hepatocellular Carcinoma
Villanueva, A., Chiang, D. Y., Newell, P., Peix, J., Thung, S., Alsinet, C., Tovar, V., Roayaie, S., Minguez, B., Sole, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.08.008 · Cited by 733
The JAK-STAT pathway at 30: Much learned, much more to do
Philips, R. L., Wang, Y., Cheon, H., Kanno, Y., Gadina, M., Sartorelli, V., Horvath, C. M., Darnell, J. E., Stark, G. R., & O’Shea, J. J. (2022) · Cell · doi:10.1016/j.cell.2022.09.023 · Cited by 720
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Ubiquitous Activation of Ras and Jak/Stat Pathways in Human HCC
Calvisi, D. F., Ladu, S., Gorden, A., Farina, M., Conner, E. A., Lee, J., Factor, V. M., & Thorgeirsson, S. S. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.01.006 · Cited by 710
Evolving cognition of the JAK-STAT signaling pathway: autoimmune disorders and cancer
Xue, C., Yao, Q., Gu, X., Shi, Q., Yuan, X., Chu, Q., Bao, Z., Lu, J., & Li, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01468-7 · Cited by 699
Drugging p53 in cancer: one protein, many targets
Hassin, O., & Oren, M. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00571-8 · Cited by 697
Sharma, A., Seow, J. J. W., Dutertre, C.-A., Pai, R., Blériot, C., Mishra, A., Wong, R. M. M., Singh, G. S. N., Sudhagar, S., Khalilnezhad, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.040 · Cited by 677
Parlesak, A., Schäfer, C., Schütz, T., Bode, J. C., & Bode, C. (2000) · Journal of Hepatology · doi:10.1016/s0168-8278(00)80242-1 · Cited by 647
Rinehart, J., Adjei, A. A., LoRusso, P. M., Waterhouse, D., Hecht, J. R., Natale, R. B., Hamid, O., Varterasian, M., Asbury, P., Kaldjian, E. P., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.01.185 · Cited by 645
Raoul, J.-L., Forner, A., Bolondi, L., Cheung, T. T., Kloeckner, R., & de Baere, T. (2019) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.11.002 · Cited by 643
The role of JAK/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours
Thomas, S. J., Snowden, J. A., Zeidler, M. P., & Danson, S. J. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.233 · Cited by 637
Cainap, C., Qin, S., Huang, W.-T., Chung, I. J., Pan, H., Cheng, Y., Kudo, M., Kang, Y.-K., Chen, P.-J., Toh, H.-C., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.3298 · Cited by 629
Hussain, S. P., Schwank, J., Staib, F., Wang, X. W., & Harris, C. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210279 · Cited by 621
Wnt–β-catenin signalling in liver development, health and disease
Perugorria, M. J., Olaizola, P., Labiano, I., Esparza-Baquer, A., Marzioni, M., Marin, J. J. G., Bujanda, L., & Banales, J. M. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0075-9 · Cited by 605
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 602
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
Llovet, J. M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., Kang, Y.-K., Assenat, E., Lim, H.-Y., Boige, V., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.3009 · Cited by 596
Tumor adaptation and resistance to RAF inhibitors
Lito, P., Rosen, N., & Solit, D. B. (2013) · Nature Medicine · doi:10.1038/nm.3392 · Cited by 585
Roles of PDGF in animal development
Hoch, R. V., & Soriano, P. (2003) · Development · doi:10.1242/dev.00721 · Cited by 585
Zhu, A. X., Rosmorduc, O., Evans, T. R. J., Ross, P. J., Santoro, A., Carrilho, F. J., Bruix, J., Qin, S., Thuluvath, P. J., Llovet, J. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.7746 · Cited by 576
Zhu, A. X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H. Y., Poon, R. T. P., Blanc, J.-F., Vogel, A., Chen, C.-L., et al. (2014) · JAMA · doi:10.1001/jama.2014.7189 · Cited by 568
Shen, J., Ju, Z., Zhao, W., Wang, L., Peng, Y., Ge, Z., Nagel, Z. D., Zou, J., Wang, C., Kapoor, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0012-z · Cited by 562
An immunomodulatory role for CD4+CD25+ regulatory T lymphocytes in hepatitis C virus infection
Cabrera, R., Tu, Z., Xu, Y., Firpi, R. J., Rosen, H. R., Liu, C., & Nelson, D. R. (2004) · Hepatology · doi:10.1002/hep.20454 · Cited by 562
Miettinen, M., & Lasota, J. (2005) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/01.pai.0000173054.83414.22 · Cited by 556
Santoro, A., Rimassa, L., Borbath, I., Daniele, B., Salvagni, S., Van Laethem, J. L., Van Vlierberghe, H., Trojan, J., Kolligs, F. T., Weiss, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70490-4 · Cited by 554
RAF-MEK-ERK pathway in cancer evolution and treatment
Ullah, R., Yin, Q., Snell, A. H., & Wan, L. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.05.010 · Cited by 553
Qin, S., Chen, M., Cheng, A.-L., Kaseb, A. O., Kudo, M., Lee, H. C., Yopp, A. C., Zhou, J., Wang, L., Wen, X., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01796-8 · Cited by 545
Self-citationHuang, D. Q., Singal, A. G., Kono, Y., Tan, D. J. H., El-Serag, H. B., & Loomba, R. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.05.003 · Cited by 534
The Role of Angiogenesis in Hepatocellular Carcinoma
Morse, M. A., Sun, W., Kim, R., He, A. R., Abada, P. B., Mynderse, M., & Finn, R. S. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1254 · Cited by 533
Yes‐associated protein is an independent prognostic marker in hepatocellular carcinoma
Xu, M. Z., Yao, T., Lee, N. P. Y., Ng, I. O. L., Chan, Y., Zender, L., Lowe, S. W., Poon, R. T. P., & Luk, J. M. (2009) · Cancer · doi:10.1002/cncr.24495 · Cited by 528
Targeting FGFR Signaling in Cancer
Touat, M., Ileana, E., Postel-Vinay, S., André, F., & Soria, J.-C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2329 · Cited by 524
PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
Tang, H., Liang, Y., Anders, R. A., Taube, J. M., Qiu, X., Mulgaonkar, A., Liu, X., Harrington, S. M., Guo, J., Xin, Y., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96061 · Cited by 524
Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma
Kan, Z., Zheng, H., Liu, X., Li, S., Barber, T. D., Gong, Z., Gao, H., Hao, K., Willard, M. D., Xu, J., et al. (2013) · Genome Research · doi:10.1101/gr.154492.113 · Cited by 523
Auto-aggressive CXCR6+ CD8 T cells cause liver immune pathology in NASH
Dudek, M., Pfister, D., Donakonda, S., Filpe, P., Schneider, A., Laschinger, M., Hartmann, D., Hüser, N., Meiser, P., Bayerl, F., et al. (2021) · Nature · doi:10.1038/s41586-021-03233-8 · Cited by 518
Kinter, A. L., Godbout, E. J., McNally, J. P., Sereti, I., Roby, G. A., O’Shea, M. A., & Fauci, A. S. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.10.6738 · Cited by 513
Understanding the complexity of p53 in a new era of tumor suppression
Liu, Y., Su, Z., Tavana, O., & Gu, W. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.04.009 · Cited by 495
TGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
Therapeutic modulation of Notch signalling — are we there yet?
Andersson, E. R., & Lendahl, U. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4252 · Cited by 457
Subbiah, V., Wolf, J., Konda, B., Kang, H., Spira, A., Weiss, J., Takeda, M., Ohe, Y., Khan, S., Ohashi, K., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00541-1 · Cited by 449
Activation of Hepatic Stem Cell Marker EpCAM by Wnt–β-Catenin Signaling in Hepatocellular Carcinoma
Yamashita, T., Budhu, A., Forgues, M., & Wang, X. W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0908 · Cited by 446
EGFR activation limits the response of liver cancer to lenvatinib
Jin, H., Shi, Y., Lv, Y., Yuan, S., Ramirez, C. F. A., Lieftink, C., Wang, L., Wang, S., Wang, C., Dias, M. H., et al. (2021) · Nature · doi:10.1038/s41586-021-03741-7 · Cited by 440
Self-citationInsight into the physiological functions of PDGF through genetic studies in mice
Betsholtz, C. (2004) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2004.03.005 · Cited by 437
Sawey, E. T., Chanrion, M., Cai, C., Wu, G., Zhang, J., Zender, L., Zhao, A., Busuttil, R. W., Yee, H., Stein, L., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.040 · Cited by 436
MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
Huang, S., Hölzel, M., Knijnenburg, T., Schlicker, A., Roepman, P., McDermott, U., Garnett, M., Grernrum, W., Sun, C., Prahallad, A., et al. (2012) · Cell · doi:10.1016/j.cell.2012.10.035 · Cited by 430
Self-citationDNA methylation‐based prognosis and epidrivers in hepatocellular carcinoma
Villanueva, A., Portela, A., Sayols, S., Battiston, C., Hoshida, Y., Méndez‐González, J., Imbeaud, S., Letouzé, E., Hernandez‐Gea, V., Cornella, H., et al. (2015) · Hepatology · doi:10.1002/hep.27732 · Cited by 428
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers
Wang, Y., & Deng, B. (2023) · Cancer and Metastasis Reviews · doi:10.1007/s10555-023-10084-4 · Cited by 415
Targeting TGFβ signal transduction for cancer therapy
Liu, S., Ren, J., & ten Dijke, P. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00436-9 · Cited by 413
New targets of β-catenin signaling in the liver are involved in the glutamine metabolism
Cadoret, A., Ovejero, C., Terris, B., Souil, E., Lévy, L., Lamers, W. H., Kitajewski, J., Kahn, A., & Perret, C. (2002) · Oncogene · doi:10.1038/sj.onc.1206118 · Cited by 410
The potential and controversy of targeting STAT family members in cancer
Verhoeven, Y., Tilborghs, S., Jacobs, J., De Waele, J., Quatannens, D., Deben, C., Prenen, H., Pauwels, P., Trinh, X. B., Wouters, A., et al. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.10.002 · Cited by 409
Qin, S., Bi, F., Gu, S., Bai, Y., Chen, Z., Wang, Z., Ying, J., Lu, Y., Meng, Z., Pan, H., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00163 · Cited by 409
Self-citationKovall, R. A., Gebelein, B., Sprinzak, D., & Kopan, R. (2017) · Developmental Cell · doi:10.1016/j.devcel.2017.04.001 · Cited by 407
mTORC2 Promotes Tumorigenesis via Lipid Synthesis
Guri, Y., Colombi, M., Dazert, E., Hindupur, S. K., Roszik, J., Moes, S., Jenoe, P., Heim, M. H., Riezman, I., Riezman, H., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.11.011 · Cited by 407
CTLA-4 blockade in tumor models: an overview of preclinical and translational research.
Grosso, J. F., & Jure‐Kunkel, M. (2013) · Europe PMC (PubMed Central) · Cited by 402
Gomes, A. L., Teijeiro, A., Burén, S., Tummala, K. S., Yilmaz, M., Waisman, A., Theurillat, J.-P., Perna, C., & Djouder, N. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.05.020 · Cited by 401
Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5818 · Cited by 399
Malehmir, M., Pfister, D., Gallage, S., Szydlowska, M., Inverso, D., Kotsiliti, E., Leone, V., Peiseler, M., Surewaard, B. G. J., Rath, D., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0379-5 · Cited by 398
Huinen, Z. R., Huijbers, E. J. M., van Beijnum, J. R., Nowak-Sliwinska, P., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 395
Abou-Alfa, G. K., Chan, S. L., Kudo, M., Lau, G., Kelley, R. K., Furuse, J., Sukeepaisarnjaroen, W., Kang, Y.-K., Dao, T. V., De Toni, E. N., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.2022.40.4_suppl.379 · Cited by 388
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma
Long, J., Wang, A., Bai, Y., Lin, J., Yang, X., Wang, D., Yang, X., Jiang, Y., & Zhao, H. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.022 · Cited by 380
Iwamaru, A., Szymanski, S., Iwado, E., Aoki, H., Yokoyama, T., Fokt, I., Hess, K., Conrad, C., Madden, T., Sawaya, R., et al. (2007) · Oncogene · doi:10.1038/sj.onc.1210031 · Cited by 370
Hepatocellular carcinoma in the setting of alcohol-related liver disease
Ganne-Carrié, N., & Nahon, P. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2018.10.008 · Cited by 360
A Mouse Model of Hepatocellular Carcinoma
Nicholes, K., Guillet, S., Tomlinson, E., Hillan, K., Wright, B., Frantz, G. D., Pham, T. A., Dillard-Telm, L., Tsai, S. P., Stephan, J.-P., et al. (2002) · The American Journal of Pathology · doi:10.1016/s0002-9440(10)61177-7 · Cited by 359
Lim, C. J., Lee, Y. H., Pan, L., Lai, L., Chua, C., Wasser, M., Lim, T. K. H., Yeong, J., Toh, H. C., Lee, S. Y., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316510 · Cited by 357
Kudo, M., Han, G., Finn, R. S., Poon, R. T. P., Blanc, J.-F., Yan, L., Yang, J., Lu, L., Tak, W.-Y., Yu, X., et al. (2014) · Hepatology · doi:10.1002/hep.27290 · Cited by 355
Xiao, X., Lao, X.-M., Chen, M.-M., Liu, R.-X., Wei, Y., Ouyang, F.-Z., Chen, D.-P., Zhao, X.-Y., Zhao, Q., Li, X.-F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1408 · Cited by 352
Rimassa, L., Assenat, E., Peck-Radosavljevic, M., Pracht, M., Zagonel, V., Mathurin, P., Rota Caremoli, E., Porta, C., Daniele, B., Bolondi, L., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30146-3 · Cited by 351
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
Hartley, G. P., Chow, L., Ammons, D. T., Wheat, W. H., & Dow, S. W. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0537 · Cited by 351
Yu, L.-X., Yan, H.-X., Liu, Q., Yang, W., Wu, H.-P., Dong, W., Tang, L., Lin, Y., He, Y.-Q., Zou, S.-S., et al. (2010) · Hepatology · doi:10.1002/hep.23845 · Cited by 349
Loh, C.-Y., Arya, A., Naema, A. F., Wong, W. F., Sethi, G., & Looi, C. Y. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00048 · Cited by 348
Notch and Wnt signals cooperatively control cell proliferation and tumorigenesis in the intestine
Fre, S., Pallavi, S. K., Huyghe, M., Laé, M., Janssen, K.-P., Robine, S., Artavanis-Tsakonas, S., & Louvard, D. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900427106 · Cited by 345
Clinical Development of BRAF plus MEK Inhibitor Combinations
Subbiah, V., Baik, C., & Kirkwood, J. M. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.05.009 · Cited by 344
The role of STAT3 in leading the crosstalk between human cancers and the immune system
Wang, Y., Shen, Y., Wang, S., Shen, Q., & Zhou, X. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.12.003 · Cited by 340
Self-citationAhn, J. C., Teng, P., Chen, P., Posadas, E., Tseng, H., Lu, S. C., & Yang, J. D. (2021) · Hepatology · doi:10.1002/hep.31165 · Cited by 338
The Role of PI3K/AKT/mTOR Signaling in Hepatocellular Carcinoma Metabolism
Tian, L.-Y., Smit, D. J., & Jücker, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032652 · Cited by 329
Phosphatidylinositol 3-kinase, growth disorders, and cancer
Goncalves, M. D., Hopkins, B. D., & Cantley, L. C. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1704560 · Cited by 327
GDNF/Ret signaling and the development of the kidney
Costantini, F., & Shakya, R. (2006) · BioEssays · doi:10.1002/bies.20357 · Cited by 327
Tschaharganeh, D. F., Chen, X., Latzko, P., Malz, M., Gaida, M. M., Felix, K., Ladu, S., Singer, S., Pinna, F., Gretz, N., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.02.009 · Cited by 326
MAPK/ERK Signaling Pathway in Hepatocellular Carcinoma
Moon, H., & Ro, S. W. (2021) · Cancers · doi:10.3390/cancers13123026 · Cited by 326
Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma
Ito, Y., Takeda, T., Sakon, M., Tsujimoto, M., Higashiyama, S., Noda, K., Miyoshi, E., Monden, M., & Matsuura, N. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1580 · Cited by 321
Tilg, H., Moschen, A. R., & Szabo, G. (2016) · Hepatology · doi:10.1002/hep.28456 · Cited by 319
Notch Signaling Is Activated in Human Hepatocellular Carcinoma and Induces Tumor Formation in Mice
Villanueva, A., Alsinet, C., Yanger, K., Hoshida, Y., Zong, Y., Toffanin, S., Rodriguez–Carunchio, L., Solé, M., Thung, S., Stanger, B. Z., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.09.002 · Cited by 318
The First Approved Gene Therapy Product for Cancer Ad- p53 (Gendicine): 12 Years in the Clinic
Zhang, W.-W., Li, L., Li, D., Liu, J., Li, X., Li, W., Xu, X., Zhang, M. J., Chandler, L. A., Lin, H., et al. (2018) · Human Gene Therapy · doi:10.1089/hum.2017.218 · Cited by 318
Tao, J., Calvisi, D. F., Ranganathan, S., Cigliano, A., Zhou, L., Singh, S., Jiang, L., Fan, B., Terracciano, L., Armeanu–Ebinger, S., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.05.004 · Cited by 317
Karlsson, L., Lindahl, P., Heath, J. K., & Betsholtz, C. (2000) · Development · doi:10.1242/dev.127.16.3457 · Cited by 316
Kong, N., Tao, W., Ling, X., Wang, J., Xiao, Y., Shi, S., Ji, X., Shajii, A., Gan, S. T., Kim, N. Y., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1565 · Cited by 314
Hagel, M., Miduturu, C., Sheets, M., Rubin, N., Weng, W., Stransky, N., Bifulco, N., Kim, J. L., Hodous, B., Brooijmans, N., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-1029 · Cited by 313
Molecular Signaling Pathways and Therapeutic Targets in Hepatocellular Carcinoma
Dimri, M., & Satyanarayana, A. (2020) · Cancers · doi:10.3390/cancers12020491 · Cited by 311
Tap, W. D., Wagner, A. J., Schöffski, P., Martin-Broto, J., Krarup-Hansen, A., Ganjoo, K. N., Yen, C.-C., Abdul Razak, A. R., Spira, A., Kawai, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.1707 · Cited by 309
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Current and future status of JAK inhibitors
McLornan, D. P., Pope, J. E., Gotlib, J., & Harrison, C. N. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00438-4 · Cited by 305
β-Catenin signaling in hepatocellular carcinoma
Xu, C., Xu, Z., Zhang, Y., Evert, M., Calvisi, D. F., & Chen, X. (2022) · Journal of Clinical Investigation · doi:10.1172/jci154515 · Cited by 305
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Pang, N., Shi, J., Qin, L., Chen, A., Tang, Y., Yang, H., Huang, Y., Wu, Q., Li, X., He, B., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01128-9 · Cited by 301
Kraemer, W. J., Ratamess, N. A., Hymer, W. C., Nindl, B. C., & Fragala, M. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00033 · Cited by 300
The BET family in immunity and disease
Wang, N., Wu, R., Tang, D., & Kang, R. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00384-4 · Cited by 295
Song, Q., Zhang, X., Liu, W., Wei, H., Liang, W., Zhou, Y., Ding, Y., Ji, F., Ho-Kwan Cheung, A., Wong, N., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.07.005 · Cited by 293
Olsen, S. K., Garbi, M., Zampieri, N., Eliseenkova, A. V., Ornitz, D. M., Goldfarb, M., & Mohammadi, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303183200 · Cited by 292
Huynh, H., Nguyen, T. T. T., Chow, K.-H. K.-P., Tan, P. H., Soo, K. C., & Tran, E. (2003) · BMC Gastroenterology · doi:10.1186/1471-230x-3-19 · Cited by 289
Single tumor-initiating cells evade immune clearance by recruiting type II macrophages
Guo, X., Zhao, Y., Yan, H., Yang, Y., Shen, S., Dai, X., Ji, X., Ji, F., Gong, X.-G., Li, L., et al. (2017) · Genes & Development · doi:10.1101/gad.294348.116 · Cited by 285
The PDGF/PDGFR pathway as a drug target
Papadopoulos, N., & Lennartsson, J. (2018) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.11.007 · Cited by 283
RET Aberrations in Diverse Cancers: Next-Generation Sequencing of 4,871 Patients
Kato, S., Subbiah, V., Marchlik, E., Elkin, S. K., Carter, J. L., & Kurzrock, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1679 · Cited by 282
Targeting the PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma
Sun, E. J., Wankell, M., Palamuthusingam, P., McFarlane, C., & Hebbard, L. (2021) · Biomedicines · doi:10.3390/biomedicines9111639 · Cited by 281
Wang, J., Yu, H., Dong, W., Zhang, C., Hu, M., Ma, W., Jiang, X., Li, H., Yang, P., & Xiang, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.01.041 · Cited by 277
The Ras/MAPK pathway and hepatocarcinoma: pathogenesis and therapeutic implications
Delire, B., & Stärkel, P. (2015) · European Journal of Clinical Investigation · doi:10.1111/eci.12441 · Cited by 275
Predictors of early and late hepatocellular carcinoma recurrence
Nevola, R., Ruocco, R., Criscuolo, L., Villani, A., Alfano, M., Beccia, D., Imbriani, S., Claar, E., Cozzolino, D., Sasso, F. C., et al. (2023) · World Journal of Gastroenterology · doi:10.3748/wjg.v29.i8.1243 · Cited by 274
Notch inhibitors for cancer treatment
Espinoza, I., & Miele, L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.02.003 · Cited by 273
Evidence for the direct involvement of βTrCP in Gli3 protein processing
Wang, B., & Li, Y. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509927103 · Cited by 273
γ-Secretase inhibitors and modulators
Golde, T. E., Koo, E. H., Felsenstein, K. M., Osborne, B. A., & Miele, L. (2013) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.06.005 · Cited by 272
Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis
Sicklick, J. K., Li, Y.-X., Jayaraman, A., Kannangai, R., Qi, Y., Vivekanandan, P., Ludlow, J. W., Owzar, K., Chen, W., Torbenson, M. S., et al. (2006) · Carcinogenesis · doi:10.1093/carcin/bgi292 · Cited by 270
Desnoyers, L. R., Pai, R., Ferrando, R. E., Hötzel, K., Le, T., Ross, J., Carano, R., D'Souza, A., Qing, J., Mohtashemi, I., et al. (2008) · Oncogene · doi:10.1038/sj.onc.1210623 · Cited by 264
Xiao, Y., Chen, J., Zhou, H., Zeng, X., Ruan, Z., Pu, Z., Jiang, X., Matsui, A., Zhu, L., Amoozgar, Z., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28279-8 · Cited by 264
Self-citationKim, R. D., Sarker, D., Meyer, T., Yau, T., Macarulla, T., Park, J.-W., Choo, S. P., Hollebecque, A., Sung, M. W., Lim, H.-Y., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0555 · Cited by 262
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Xu, Y., Poggio, M., Jin, H. Y., Shi, Z., Forester, C. M., Wang, Y., Stumpf, C. R., Xue, L., Devericks, E., So, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0321-2 · Cited by 261
Self-citationSyn, W., Jung, Y., Omenetti, A., Abdelmalek, M., Guy, C. D., Yang, L., Wang, J., Witek, R. P., Fearing, C. M., Pereira, T. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.051 · Cited by 258
Targeting telomerase for cancer therapy
Guterres, A. N., & Villanueva, J. (2020) · Oncogene · doi:10.1038/s41388-020-01405-w · Cited by 256
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Montironi, C., Castet, F., Haber, P. K., Pinyol, R., Torres-Martin, M., Torrens, L., Mesropian, A., Wang, H., Puigvehi, M., Maeda, M., et al. (2023) · Gut · doi:10.1136/gutjnl-2021-325918 · Cited by 253
Metadata
- Authors
- Zheng, J., Wang, S., Xia, L., Sun, Z., Chan, K. M., Bernards, R., Qin, W., Chen, J., Xia, Q., & Jin, H.
- Venue
- Signal Transduction and Targeted Therapy
- Published
- 2025-02-07
- Volume
- 10
- Issue
- 1
- Pages
- 35-35
- ISSN
- 2059-3635 (ISSN-L)
- OpenAlex
- W4407203105
- Cited by
- 341
- References
- 641
- FWCI
- 165.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.